They Call It a Lottery Ticket. The Data Says Otherwise | The Hidden Alpha of Biotech
TL;DR
Biotech investing is not gambling but a systematic 'bag of options' exercise where specialist investors can generate persistent alpha by probability-weighting drug development pipelines, though the sector experiences violent capital cycles driven by interest rates and competition from technology narratives like AI.
💊 The 'Bag of Options' Framework 3 insights
Development-stage firms as option portfolios
Early-stage biotech companies represent collections of call options on future drug approvals rather than traditional cash-flow businesses, with valuation requiring a sum-of-the-parts analysis of each independent program.
Probability-weighted valuation math
Investors calculate net present value by multiplying potential market size by phase-specific success probabilities—where preclinical drugs carry only 5-10% approval odds—and discounting cash flows occurring 8-10 years in the future.
Extreme duration risk
These companies exhibit severe sensitivity to interest rate changes because nearly 100% of their value derives from distant future cash flows, making valuations vulnerable to discount rate volatility.
🎯 Exploiting Information Asymmetry 3 insights
Domain expertise creates market inefficiency
Unlike efficient markets theory, biotech offers persistent alpha because proper valuation requires processing highly specialized scientific information that generalist investors cannot easily access or analyze.
Base rate analysis by modality
Successful investors anchor probability estimates using historical transition rates between clinical phases, adjusting for specific drug types such as antibodies versus small molecules to create precise reference classes.
Dual-variable valuation challenge
Accurate pricing depends on correctly estimating both the probability of technical success and the ultimate commercial opportunity (TAM), including uncertainties around pricing power and market share capture.
📈 Capital Cycles and Market Timing 3 insights
The COVID boom-bust cycle
The sector experienced extreme enthusiasm during the pandemic driven by mRNA vaccine success, followed by a 2022-2024 contraction as rising interest rates and capital rotation into AI/big tech drained risk capital from biotech.
2025 resurgence
Capital began flowing back into biotech by mid-2025, driving passive index returns of 80-100% as risk appetite returned and the sector emerged from its cyclical trough.
AI as capital competitor
Despite transformative narratives from figures like Jensen Huang, AI primarily competes with biotech for risk capital rather than driving sector inflows, with large pharma using AI stories to attract investment without establishing durable competitive advantages.
Bottom Line
Treat biotech companies as probability-weighted option portfolios and apply specialized domain knowledge to identify mispricings during periods of cyclical capital dislocation when generalist investors flee the sector.
More from Excess Returns
View all
We Asked GMO’s Head of Asset Allocation Why This Bubble is Easy — But Investors Will Get it Wrong
GMO's Ben Inker argues the current AI-driven US stock bubble is "easy" to navigate because investors can rotate to fairly priced international assets while maintaining normal risk levels, unlike the "hard" bubbles of 2007 and 2021 when all risk assets were simultaneously overvalued.
Expensive Market. Record Issuance. Can the Story Still Hold It Up? | 6 Things We Learned This Week
Valuation expert Aswath Damodaran, IPO strategist Andy Constan, and value investor Tobias Carlisle discuss how to value story-driven companies like SpaceX, why issuers intentionally underprice IPOs, and why investors should avoid market timing despite extreme overvaluation by targeting undervalued segments like small-cap value.
The $2 Trillion Question | Tobias Carlisle on SpaceX, the AI Buildout, and the Rotation No One Sees
Tobias Carlisle warns that the market is at historic valuation extremes comparable to the dot-com bubble, but argues investors should rotate into deeply undervalued small and micro-cap value stocks rather than exit entirely, as early indicators suggest a potential decade-long rotation away from large-cap growth; meanwhile, he cautions that the massive AI infrastructure buildout risks following historical boom-bust patterns where value accrues to consumers, not creators.
The Trillion-Dollar Gap | We Asked Aswath Damodaran What SpaceX Is Really Worth
Finance professor Aswath Damodaran analyzes SpaceX's $2.7 trillion valuation, finding that while the space launch and Starlink businesses hold real competitive advantages, the AI division's projected $26 trillion market relies on terrible unit economics and a contradictory strategy of renting data centers to direct competitors.